Quantity of eligible patients: CDEC discussed the uncertainty in the number of people with reasonably significant to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some clients who're classified as having moderate or reasonable illness may have a severe bleeding phenotype, which https://tysonrciot.bloggin-ads.com/59186360/5-simple-statements-about-hemgenix-explained